{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:59:06Z","timestamp":1791896346266,"version":"4.3.4"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-020-00167-4","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T12:03:47Z","timestamp":1611230627000},"page":"284-299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"2","author":[{"given":"Yoshihiro","family":"Gocho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8184-8382","authenticated-orcid":false,"given":"Jingjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5048-067X","authenticated-orcid":false,"given":"Neekesh V.","family":"Dharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingliao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"August","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Nien","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bensheng","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Smart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-558X","authenticated-orcid":false,"given":"Kristine R.","family":"Crews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7626-4043","authenticated-orcid":false,"given":"Kathryn","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartholomew","family":"Eisfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Paietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Roti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Easton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3350-9682","authenticated-orcid":false,"given":"Jinghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0472-7648","authenticated-orcid":false,"given":"Junmin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9167-2114","authenticated-orcid":false,"given":"Stanley","family":"Pounds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3720-9591","authenticated-orcid":false,"given":"Mary V.","family":"Relling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0605-7342","authenticated-orcid":false,"given":"Hiroto","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-9548","authenticated-orcid":false,"given":"Steven","family":"Kornblau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0303-5658","authenticated-orcid":false,"given":"Ching-Hon","family":"Pui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-8987","authenticated-orcid":false,"given":"David","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-1850","authenticated-orcid":false,"given":"Charles G.","family":"Mullighan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0218-7895","authenticated-orcid":false,"given":"Kimberly","family":"Stegmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-5322","authenticated-orcid":false,"given":"William E.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3629-4330","authenticated-orcid":false,"given":"Jiyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0770-9659","authenticated-orcid":false,"given":"Jun J.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"key":"167_CR1","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","volume":"33","author":"CH Pui","year":"2015","unstructured":"Pui, C. H. et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J. Clin. Oncol. 33, 2938\u20132948 (2015).","journal-title":"J. Clin. Oncol."},{"key":"167_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger, S. P. & Mullighan, C. G. Acute lymphoblastic leukemia in children. N. Engl. J. Med. 373, 1541\u20131552 (2015).","journal-title":"N. Engl. J. Med."},{"key":"167_CR3","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","volume":"36","author":"WB Slayton","year":"2018","unstructured":"Slayton, W. B. et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of children\u2019s oncology group trial AALL0622. J. Clin. Oncol. 36, 2306\u20132314 (2018).","journal-title":"J. Clin. Oncol."},{"key":"167_CR4","doi-asserted-by":"publisher","unstructured":"Shen, S. et al. Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2019.5868 (2020).","DOI":"10.1001\/jamaoncol.2019.5868"},{"key":"167_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371, 1005\u20131015 (2014).","journal-title":"N. Engl. J. Med."},{"key":"167_CR6","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","volume":"2016","author":"EA Raetz","year":"2016","unstructured":"Raetz, E. A. & Teachey, D. T. T-cell acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program 2016, 580\u2013588 (2016).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"167_CR7","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","volume":"129","author":"T Girardi","year":"2017","unstructured":"Girardi, T., Vicente, C., Cools, J. & De Keersmaecker, K. The genetics and molecular biology of T-ALL. Blood 129, 1113\u20131123 (2017).","journal-title":"Blood"},{"key":"167_CR8","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211\u20131218 (2017).","journal-title":"Nat. Genet."},{"key":"167_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11899-019-00501-3","volume":"14","author":"CM McMahon","year":"2019","unstructured":"McMahon, C. M. & Luger, S. M. Relapsed T cell ALL: current approaches and new directions. Curr. Hematol. Malig. Rep. 14, 83\u201393 (2019).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"167_CR10","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/leu.2008.251","volume":"22","author":"K Nguyen","year":"2008","unstructured":"Nguyen, K. et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Leukemia 22, 2142\u20132150 (2008).","journal-title":"Leukemia"},{"key":"167_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrclinonc.2017.176","volume":"15","author":"DT Teachey","year":"2018","unstructured":"Teachey, D. T. & Hunger, S. P. Acute lymphoblastic leukaemia in 2017: immunotherapy for ALL takes the world by storm. Nat. Rev. Clin. Oncol. 15, 69\u201370 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"167_CR12","doi-asserted-by":"publisher","first-page":"S205","DOI":"10.3816\/CLM.2009.s.013","volume":"9","author":"T Palomero","year":"2009","unstructured":"Palomero, T. & Ferrando, A. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. Clin. Lymphoma Myeloma 9, S205\u2013S210 (2009).","journal-title":"Clin. Lymphoma Myeloma"},{"key":"167_CR13","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1586\/era.11.73","volume":"11","author":"LM Sarmento","year":"2011","unstructured":"Sarmento, L. M. & Barata, J. T. Therapeutic potential of Notch inhibition in T-cell acute lymphoblastic leukemia: rationale, caveats and promises. Expert Rev. Anticancer Ther. 11, 1403\u20131415 (2011).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"167_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.pharmthera.2013.09.005","volume":"141","author":"N Takebe","year":"2014","unstructured":"Takebe, N., Nguyen, D. & Yang, S. X. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol. Ther. 141, 140\u2013149 (2014).","journal-title":"Pharmacol. Ther."},{"key":"167_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody, R. S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N. Engl. J. Med. 369, 341\u2013350 (2013).","journal-title":"N. Engl. J. Med."},{"key":"167_CR16","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","volume":"16","author":"C Le Tourneau","year":"2015","unstructured":"Le Tourneau, C. et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16, 1324\u20131334 (2015).","journal-title":"Lancet Oncol."},{"key":"167_CR17","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","volume":"25","author":"JK Sicklick","year":"2019","unstructured":"Sicklick, J. K. et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat. Med. 25, 744\u2013750 (2019).","journal-title":"Nat. Med."},{"key":"167_CR18","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.4389","volume":"23","author":"A Letai","year":"2017","unstructured":"Letai, A. Functional precision cancer medicine-moving beyond pure genomics. Nat. Med. 23, 1028\u20131035 (2017).","journal-title":"Nat. Med."},{"key":"167_CR19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukaemia. Nature 562, 526\u2013531 (2018).","journal-title":"Nature"},{"key":"167_CR20","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/s41588-018-0209-6","volume":"50","author":"JK Lee","year":"2018","unstructured":"Lee, J. K. et al. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat. Genet. 50, 1399\u20131411 (2018).","journal-title":"Nat. Genet."},{"key":"167_CR21","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920\u2013926 (2018).","journal-title":"Science"},{"key":"167_CR22","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","volume":"129","author":"V Frismantas","year":"2017","unstructured":"Frismantas, V. et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 129, e26\u2013e37 (2017).","journal-title":"Blood"},{"key":"167_CR23","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1016\/S2352-3026(17)30208-9","volume":"4","author":"B Snijder","year":"2017","unstructured":"Snijder, B. et al. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematol. 4, e595\u2013e606 (2017).","journal-title":"Lancet Haematol"},{"key":"167_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa033513","volume":"351","author":"A Holleman","year":"2004","unstructured":"Holleman, A. et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 351, 533\u2013542 (2004).","journal-title":"N. Engl. J. Med."},{"key":"167_CR25","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/nm.2430","volume":"17","author":"B Diouf","year":"2011","unstructured":"Diouf, B. et al. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat. Med. 17, 1298\u20131303 (2011).","journal-title":"Nat. Med."},{"key":"167_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0658-0","volume":"17","author":"P Putcha","year":"2015","unstructured":"Putcha, P. et al. HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Res. 17, 149 (2015).","journal-title":"Breast Cancer Res."},{"key":"167_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/s41588-018-0138-4","volume":"50","author":"MJ Alvarez","year":"2018","unstructured":"Alvarez, M. J. et al. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nat. Genet. 50, 979\u2013989 (2018).","journal-title":"Nat. Genet."},{"key":"167_CR28","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.ccr.2013.10.022","volume":"24","author":"E Piovan","year":"2013","unstructured":"Piovan, E. et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 24, 766\u2013776 (2013).","journal-title":"Cancer Cell"},{"key":"167_CR29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrd2135","volume":"5","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian, H., Jabbour, E., Grimley, J. & Kirkpatrick, P. Dasatinib. Nat. Rev. Drug Discov. 5, 717\u2013718 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"167_CR30","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3563","volume":"13","author":"EK Greuber","year":"2013","unstructured":"Greuber, E. K., Smith-Pearson, P., Wang, J. & Pendergast, A. M. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat. Rev. Cancer 13, 559\u2013571 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"167_CR31","doi-asserted-by":"publisher","first-page":"9185","DOI":"10.1158\/0008-5472.CAN-05-1731","volume":"65","author":"S Nam","year":"2005","unstructured":"Nam, S. et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 65, 9185\u20139189 (2005).","journal-title":"Cancer Res."},{"key":"167_CR32","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1158\/1535-7163.MCT-09-0151","volume":"8","author":"P Ceppi","year":"2009","unstructured":"Ceppi, P. et al. Effects of Src kinase inhibition induced by dasatinib in non\u2013small cell lung cancer cell lines treated with cisplatin. Mol. Cancer Ther. 8, 3066\u20133074 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"167_CR33","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1182\/blood-2017-05-784603","volume":"130","author":"V Serafin","year":"2017","unstructured":"Serafin, V. et al. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. Blood 130, 2750\u20132761 (2017).","journal-title":"Blood"},{"key":"167_CR34","doi-asserted-by":"publisher","first-page":"e604","DOI":"10.1038\/bcj.2017.87","volume":"7","author":"S Laukkanen","year":"2017","unstructured":"Laukkanen, S. et al. In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. Blood Cancer J. 7, e604 (2017).","journal-title":"Blood Cancer J."},{"key":"167_CR35","first-page":"241026","volume":"2019","author":"Y Shi","year":"2020","unstructured":"Shi, Y. et al. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia. Haematologica 2019, 241026 (2020).","journal-title":"Haematologica"},{"key":"167_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3324\/haematol.2013.088674","volume":"99","author":"De,K Kim","year":"2014","unstructured":"Kim, De,K. et al. NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins. Haematologica 99, 85\u201393 (2014).","journal-title":"Haematologica"},{"key":"167_CR37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-018-0177-0","volume":"558","author":"X Du","year":"2018","unstructured":"Du, X. et al. Hippo\/Mst signalling couples metabolic state and immune function of CD8\u03b1+ dendritic cells. Nature 558, 141\u2013145 (2018).","journal-title":"Nature"},{"key":"167_CR38","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1093\/bioinformatics\/bty907","volume":"35","author":"A Khatamian","year":"2019","unstructured":"Khatamian, A., Paull, E. O., Califano, A. & Yu, J. SJARACNe: a scalable software tool for gene network reverse engineering from big data. Bioinformatics 35, 2165\u20132166 (2019).","journal-title":"Bioinformatics"},{"key":"167_CR39","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2017","unstructured":"Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074\u2013D1082 (2017).","journal-title":"Nucleic Acids Res."},{"key":"167_CR40","doi-asserted-by":"publisher","first-page":"D1068","DOI":"10.1093\/nar\/gkx1143","volume":"46","author":"KC Cotto","year":"2017","unstructured":"Cotto, K. C. et al. DGIdb 3.0: a redesign and expansion of the drug\u2013gene interaction database. Nucleic Acids Res. 46, D1068\u2013D1073 (2017).","journal-title":"Nucleic Acids Res."},{"key":"167_CR41","doi-asserted-by":"publisher","first-page":"eaan4368","DOI":"10.1126\/science.aan4368","volume":"358","author":"S Klaeger","year":"2017","unstructured":"Klaeger, S. et al. The target landscape of clinical kinase drugs. Science 358, eaan4368 (2017).","journal-title":"Science"},{"key":"167_CR42","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/cyto.a.22070","volume":"81","author":"AM Nyakeriga","year":"2012","unstructured":"Nyakeriga, A. M., Garg, H. & Joshi, A. TCR-induced T cell activation leads to simultaneous phosphorylation at Y505 and Y394 of p56(lck) residues. Cytometry A 81, 797\u2013805 (2012).","journal-title":"Cytometry A"},{"key":"167_CR43","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","volume":"3","author":"EW Weber","year":"2019","unstructured":"Weber, E. W. et al. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 3, 711\u2013717 (2019).","journal-title":"Blood Adv."},{"key":"167_CR44","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1093\/emboj\/18.7.1832","volume":"18","author":"BL Williams","year":"1999","unstructured":"Williams, B. L. et al. Phosphorylation of Tyr319 in ZAP-70 is required for T-cell antigen receptor-dependent phospholipase C-\u03b31 and Ras activation. EMBO J. 18, 1832\u20131844 (1999).","journal-title":"EMBO J."},{"key":"167_CR45","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/leu.2010.11","volume":"24","author":"KC Lee","year":"2010","unstructured":"Lee, K. C. et al. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia 24, 896\u2013900 (2010).","journal-title":"Leukemia"},{"key":"167_CR46","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1021\/jm060435i","volume":"49","author":"MW Martin","year":"2006","unstructured":"Martin, M. W. et al. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J. Med. Chem. 49, 4981\u20134991 (2006).","journal-title":"J. Med. Chem."},{"key":"167_CR47","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1021\/jm501562a","volume":"58","author":"GJ Roth","year":"2015","unstructured":"Roth, G. J. et al. Nintedanib: from discovery to the clinic. J. Med. Chem. 58, 1053\u20131063 (2015).","journal-title":"J. Med. Chem."},{"key":"167_CR48","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/ng.3900","volume":"49","author":"M Seki","year":"2017","unstructured":"Seki, M. et al. Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat. Genet. 49, 1274\u20131281 (2017).","journal-title":"Nat. Genet."},{"key":"167_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nri2232","volume":"8","author":"EV Rothenberg","year":"2008","unstructured":"Rothenberg, E. V., Moore, J. E. & Yui, M. A. Launching the T-cell-lineage developmental programme. Nat. Rev. Immunol. 8, 9\u201321 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"167_CR50","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/ni.2590","volume":"14","author":"M Mingueneau","year":"2013","unstructured":"Mingueneau, M. et al. The transcriptional landscape of \u03b1\u03b2 T cell differentiation. Nat. Immunol. 14, 619\u2013632 (2013).","journal-title":"Nat. Immunol."},{"key":"167_CR51","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile, T. N. et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 4, 1074\u20131087 (2014).","journal-title":"Cancer Discov."},{"key":"167_CR52","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1073\/pnas.062050599","volume":"99","author":"D Bellavia","year":"2002","unstructured":"Bellavia, D. et al. Combined expression of pT\u03b1 and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc. Natl Acad. Sci. USA 99, 3788\u20133793 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"167_CR53","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1182\/blood-2006-09-048801","volume":"109","author":"NR dos Santos","year":"2007","unstructured":"dos Santos, N. R. et al. Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia. Blood 109, 3972\u20133981 (2007).","journal-title":"Blood"},{"key":"167_CR54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.it.2006.11.006","volume":"28","author":"S Yamasaki","year":"2007","unstructured":"Yamasaki, S. & Saito, T. Molecular basis for pre-TCR-mediated autonomous signaling. Trends Immunol. 28, 39\u201343 (2007).","journal-title":"Trends Immunol."},{"key":"167_CR55","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1084\/jem.182.3.821","volume":"182","author":"DT Chao","year":"1995","unstructured":"Chao, D. T. et al. Bcl-XL and Bcl-2 repress a common pathway of cell death. J. Exp. Med. 182, 821\u2013828 (1995).","journal-title":"J. Exp. Med."},{"key":"167_CR56","doi-asserted-by":"publisher","first-page":"10685","DOI":"10.1073\/pnas.91.22.10685","volume":"91","author":"J Gratiot-Deans","year":"1994","unstructured":"Gratiot-Deans, J., Merino, R., Nu\u00f1ez, G. & Turka, L. A. Bcl-2 expression during T-cell development: early loss and late return occur at specific stages of commitment to differentiation and survival. Proc. Natl Acad. Sci. USA 91, 10685\u201310689 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"167_CR57","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.19.01692","volume":"37","author":"S Jeha","year":"2019","unstructured":"Jeha, S. et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16. J. Clin. Oncol. 37, 3377\u20133391 (2019).","journal-title":"J. Clin. Oncol."},{"key":"167_CR58","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2012.46.8280","volume":"31","author":"CM Zwaan","year":"2013","unstructured":"Zwaan, C. M. et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the innovative therapies for children with cancer consortium. J. Clin. Oncol. 31, 2460\u20132468 (2013).","journal-title":"J. Clin. Oncol."},{"key":"167_CR59","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1200\/JCO.2010.30.7231","volume":"29","author":"R Aplenc","year":"2011","unstructured":"Aplenc, R. et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children\u2019s oncology group phase I consortium. J.Clin. Oncol. 29, 839\u2013844 (2011).","journal-title":"J.Clin. Oncol."},{"key":"167_CR60","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-13-0306","volume":"19","author":"A Broniscer","year":"2013","unstructured":"Broniscer, A. et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin. Cancer Res. 19, 3050\u20133058 (2013).","journal-title":"Clin. Cancer Res."},{"key":"167_CR61","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1101\/gr.209163.116","volume":"27","author":"M Qian","year":"2017","unstructured":"Qian, M. et al. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. Genome Res. 27, 185\u2013195 (2017).","journal-title":"Genome Res."},{"key":"167_CR62","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","volume":"373","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. Germline mutations in predisposition genes in pediatric cancer. New Engl. J. Med. 373, 2336\u20132346 (2015).","journal-title":"New Engl. J. Med."},{"key":"167_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06485-7","volume":"9","author":"M Rusch","year":"2018","unstructured":"Rusch, M. et al. Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. Nat. Commun. 9, 3962 (2018).","journal-title":"Nat. Commun."},{"key":"167_CR64","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nmeth.3394","volume":"12","author":"X Chen","year":"2015","unstructured":"Chen, X. et al. CONSERTING: integrating copy-number analysis with structural-variation detection. Nat. Methods 12, 527\u2013530 (2015).","journal-title":"Nat. Methods"},{"key":"167_CR65","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nmeth.1628","volume":"8","author":"J Wang","year":"2011","unstructured":"Wang, J. et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat. Methods 8, 652\u2013654 (2011).","journal-title":"Nat. Methods"},{"key":"167_CR66","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/bioinformatics\/btn624","volume":"25","author":"S Pounds","year":"2009","unstructured":"Pounds, S. et al. Reference alignment of SNP microarray signals for copy number analysis of tumors. Bioinformatics 25, 315\u2013321 (2009).","journal-title":"Bioinformatics"},{"key":"167_CR67","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1172\/JCI30235","volume":"117","author":"S Iwamoto","year":"2007","unstructured":"Iwamoto, S., Mihara, K., Downing, J. R., Pui, C. H. & Campana, D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J. Clin. Invest. 117, 1049\u20131057 (2007).","journal-title":"J. Clin. Invest."},{"key":"167_CR68","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR\u2013Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779\u20131784 (2017).","journal-title":"Nat. Genet."},{"key":"167_CR69","doi-asserted-by":"crossref","unstructured":"Dempster, J. M. et al. Extracting biological insights from the project Achilles genome-scale CRISPR screens in cancer cell lines. Preprint at: bioRxiv https:\/\/www.biorxiv.org\/content\/10.1101\/720243v1 (2019).","DOI":"10.1101\/720243"},{"key":"167_CR70","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Series B Stat. Methodol."},{"key":"167_CR71","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"167_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-10-22","volume":"10","author":"D Smedley","year":"2009","unstructured":"Smedley, D. et al. BioMart\u2013biological queries made easy. BMC Genomics 10, 22 (2009).","journal-title":"BMC Genomics"},{"key":"167_CR73","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/ni.3299","volume":"16","author":"D Casero","year":"2015","unstructured":"Casero, D. et al. Long non-coding RNA profiling of human lymphoid progenitor cells reveals transcriptional divergence of B cell and T cell lineages. Nat. Immunol. 16, 1282\u20131291 (2015).","journal-title":"Nat. Immunol."},{"key":"167_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11661-4","volume":"10","author":"H Wang","year":"2019","unstructured":"Wang, H. et al. Deep multiomics profiling of brain tumors identifies signaling networks downstream of cancer driver genes. Nat. Commun. 10, 3718 (2019).","journal-title":"Nat. Commun."},{"key":"167_CR75","doi-asserted-by":"publisher","first-page":"D261","DOI":"10.1093\/nar\/gkr1122","volume":"40","author":"PV Hornbeck","year":"2011","unstructured":"Hornbeck, P. V. et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 40, D261\u2013D270 (2011).","journal-title":"Nucleic Acids Res."},{"key":"167_CR76","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2018-04-845628","volume":"132","author":"J Zhang","year":"2018","unstructured":"Zhang, J. et al. FLT3 pathway is a potential therapeutic target for PRC2-mutated T-cell acute lymphoblastic leukemia. Blood 132, 2520\u20132524 (2018).","journal-title":"Blood"},{"key":"167_CR77","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nmeth.4236","volume":"14","author":"VY Kiselev","year":"2017","unstructured":"Kiselev, V. Y. et al. SC3: consensus clustering of single-cell RNA-seq data. Nat. Methods 14, 483\u2013486 (2017).","journal-title":"Nat. Methods"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-020-00167-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-020-00167-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-020-00167-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T16:19:13Z","timestamp":1724343553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-020-00167-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":77,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["167"],"URL":"https:\/\/doi.org\/10.1038\/s43018-020-00167-4","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"assertion":[{"value":"17 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.V.D. is a current employee of Genentech, Inc., a member of the Roche Group. S.N. is a current employee of Sema4 Inc. K.S. currently has funding from Novartis International AG and has previously consulted for Rigel Pharmaceuticals on topics unrelated to this manuscript. M.V.R. J.J.Y. and St. Jude receive investigator-initiated research funding from Servier for work unrelated to this manuscript. J.J.Y. and J.Y. are also named as co-inventors on a pending provisional US patent application filed by St. Jude based on this research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}